Amivantamab

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung cancer, according to the agents’ manufacturer.

In this video, J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, discusses the changing treatment landscape in EGFR-mutated lung cancer.

Lung Cancer Awareness Month, observed every November, is intended to educate the public about the potential causes and risk factors of the disease.

In this edition, FDA approves Rybrevant for advanced lung cancer, screening orders in eligible patients higher with digital health program and more.

The FDA approved amivantamab-vmjw in combination with standard chemotherapy for the treatment of certain adults with non-small cell lung cancer, according to the agent’s manufacturer.

The FDA approved amivantamab-vmjw plus lazertinib as first-line treatment for certain adults with non-small cell lung cancer.

In this edition, screening program identifies airways disease in previously undiagnosed COPD, positive results show benefits of subcutaneous bispecifics and more.

CHICAGO — The addition of subcutaneous amivantamab to lazertinib demonstrated noninferior pharmacokinetics and objective response rate compared with intravenous amivantamab, results from a phase 3 study showed.

MADRID — Healio spoke with Hossein Borghaei, DO, MS, about the results of the MARIPOSA-2 trial, which were presented at ESMO Congress.